-
Overview
Date & Location
03/19/2021 – 03/19/2021, 12:00 AM CST Online
Overview
This episode reflects on the progression of COVID treatments one year in, and discusses the biggest advances in the treatment for COVID-19 over the past year. Lessons learned from the ACT2 trial study are discussed as well as lessons learned from other trials. Preliminary studies on monulpiravir, and oral antiviral drug, is also discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 6
- Discuss the biggest advances in COVID-19.
- Discuss beneficial agents in preventing COVID-19.
- Discuss the role of anti-virals in the treatment of COVID-19.
- Discuss preliminary studies of monulpiravir.
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
University of Texas Health Science Center at San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
University of Texas Health Science Center at San Antonio designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 03/19/2021 Credits expire: 03/19/2022
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Phil Ponce, MD
Assistant Professor of Medicine/Infectious Diseases
Joe R. and Teresa Lozano Long School of Medicine
UT Health San Antonio
Medical Director Transplant Infectious Diseases, University HealthDr. Ponce is currently an Assistant Professor of Infectious Diseases at UT Health San Antonio. His usual clinical responsibilities include serving as the Director of Transplant ID at the University Transplant Center and the Medical Director of the Kind Clinic, a nonprofit clinic focused on STI testing and treatment, HIV prevention, and HIV care. Since the advent of the COVID epidemic he has been a site co-investigator on the NIH ACTT and ACTIV clinical trials at UT Health San Antonio. He is the COVID ID liaison to the Hospital Medicine service, helping to develop the University Hospital treatment protocols, and is a regular attending on the inpatient COVID ID consult service.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial and recieves honorarium from Pfizer.
Dr. Phil Ponce has disclosed that he is NIH ACTT co-investigator and sub-investigator on the Novavax SARS-Co-V-2 vaccine trial.
